001     902213
005     20230123110539.0
024 7 _ |a 10.1002/ana.26262
|2 doi
024 7 _ |a 0364-5134
|2 ISSN
024 7 _ |a 1531-8249
|2 ISSN
024 7 _ |a 2128/29661
|2 Handle
024 7 _ |a altmetric:116123503
|2 altmetric
024 7 _ |a pmid:34724243
|2 pmid
024 7 _ |a WOS:000720889800001
|2 WOS
037 _ _ |a FZJ-2021-04101
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Schweitzer, Finja
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Cerebrospinal Fluid Analysis Post–COVID-19 Is Not Suggestive of Persistent Central Nervous System Infection
260 _ _ |a Hoboken, NJ
|c 2022
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1640854699_26358
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a This study was undertaken to assess whether SARS-CoV-2 causes a persistent central nervous system infection. SARS-CoV-2–specific antibody index and SARS-CoV-2 RNA were studied in cerebrospinal fluid following COVID-19. Cerebrospinal fluid was assessed between days 1 and 30 (n = 12), between days 31 and 90 (n = 8), or later than 90 days (post–COVID-19, n = 20) after COVID-19 diagnosis. SARS-CoV-2 RNA was absent in all patients, and in none of the 20 patients with post–COVID-19 syndrome were intrathecally produced anti–SARS-CoV-2 antibodies detected. The absence of evidence of SARS-CoV-2 in cerebrospinal fluid argues against a persistent central nervous system infection as a cause of neurological or neuropsychiatric post–COVID-19 syndrome. ANN NEUROL 2022;91:150–157
536 _ _ |a 5251 - Multilevel Brain Organization and Variability (POF4-525)
|0 G:(DE-HGF)POF4-5251
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Goereci, Yasemin
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Franke, Christiana
|0 0000-0002-5609-2472
|b 2
700 1 _ |a Silling, Steffi
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Bösl, Fabian
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Maier, Franziska
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Heger, Eva
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Deiman, Birgit
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Prüss, Harald
|0 0000-0002-8283-7976
|b 8
700 1 _ |a Onur, Oezguer A.
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Klein, Florian
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Fink, Gereon Rudolf
|0 P:(DE-Juel1)131720
|b 11
|u fzj
700 1 _ |a Di Cristanziano, Veronica
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Warnke, Clemens
|0 0000-0002-3510-9255
|b 13
|e Corresponding author
773 _ _ |a 10.1002/ana.26262
|g p. ana.26262
|0 PERI:(DE-600)2037912-2
|n 1
|p 150-157
|t Annals of neurology
|v 91
|y 2022
|x 1531-8249
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/902213/files/Annals%20of%20Neurology%20-%202021%20-%20Schweitzer%20-%20Cerebrospinal%20Fluid%20Analysis%20Post%20COVID%25u201019%20Is%20Not%20Suggestive%20of%20Persistent.pdf
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/902213/files/Schweitzer_2021_Ann%20Neurol_CSF%20analysis%20in%20..._accepted%20proof%20%28002%29.pdf
909 C O |o oai:juser.fz-juelich.de:902213
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 2
|6 0000-0002-5609-2472
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 8
|6 0000-0002-8283-7976
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 11
|6 P:(DE-Juel1)131720
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 13
|6 0000-0002-3510-9255
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5251
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-03
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2021-02-03
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-03
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-30
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANN NEUROL : 2021
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-30
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-30
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ANN NEUROL : 2021
|d 2022-11-30
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21